The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Quality of life of patients with mild hypertension treated with captopril: a randomized double-blind placebo-controlled clinical trial.
OBJECTIVE To determine the quality of life ( QOL ) of mild hypertensive patients treated with captopril as compared to placebo . METHODS This is a r and omized , double-blind , placebo-controlled clinical trial held in the out-patient clinic of Zhong Shan Hospital . Adult patients aged from 28 to 75 years with mild hypertension defined as diastolic blood pressure from 90 to 105 mm Hg were the inclusion criteria of the study . There were 278 patients who were eligible to enter the study . They were r and omized to receive captopril or placebo 25 to 50 mg bid for 12 weeks . Change of QOL was compared both quantitatively and qualitatively between captopril and placebo groups . Change of blood pressure and side effects were also compared . RESULTS With intention-to-treat analysis , significantly more improved QOL patients could be found qualitatively in patients with captopril treatment ( 45.3 % vs 23.7 % , P = 0.0002 for physical health domain ; 48.9 % vs 26.6 % , P = 0.0002 for mental health domain ; 33.8 % vs 11.5 % , P = 0.0001 for general function domain ) . Quantitatively , the change of score of mental health , general function and total QOL of captopril ( 3.18 + /- 5.90 ; 1.65 + /- 4.43 ; 7.84 + /- 11.03 ) were significantly higher than those of placebo ( 1.32 + /- 5.13 , P = 0.00004 ; 0.64 + /- 3.45 , P = 0.0008 ; 4.19 + /- 10.33 , P = 0.0025 respectively ) , and the change of score of physical health domain ( 3.01 + /- 5.26 vs 2.23 + /- 4.79 , P = 0.044 ) was of borderline statistical significant difference . Blood pressure was significantly lowered by captopril than by placebo ( P = 0.000 ) . CONCLUSION Compared with the placebo , captopril is not only effective in lowering blood pressure , as has been established , but also effective in improving QOL in mild hypertensives
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .